LiDCO says that it is on track to meet 2019-20 expectations.
The patient monitoring equipment developer increased product sales by 10% to £3.33m in the first half, thanks to strong growth in the US and rest of the world. There was a 9% fall in the UK.
High usage programme licence revenue more than doubled and annualised revenues are £2.1m. Total revenues were 4% ahead at £3.5m, because of the loss of a distributorship for a third party product.
Net cash was £1.2m at the end of July 2019.
© 2019 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Omega Diagnostics will lose money this year, but it is on course to become profitable in 2020-21 as sales of the VISITECT CD4 test.
House broker Shore Capital has slashed its pre-tax profit forecast for engineer Tricorn Group by two-thirds to £420,000.
Evgen Pharma has entered into an agreement with The University of Dundee for the use of SFX-01 in a clinical trial in non-alcoholic steatohepatitis and liver fibrosis, where there is no existing treatment.